Brokerages Set Sarepta Therapeutics, Inc. (NASDAQ:SRPT) PT at $175.55

Shares of Sarepta Therapeutics, Inc. (NASDAQ:SRPT) have been assigned a consensus recommendation of “Moderate Buy” from the twenty-two analysts that are currently covering the company, Marketbeat Ratings reports. One equities research analyst has rated the stock with a sell recommendation, one has assigned a hold recommendation, nineteen have issued a buy recommendation and one has given a strong buy recommendation to the company. The average twelve-month price target among brokers that have updated their coverage on the stock in the last year is $178.71.

A number of equities research analysts have weighed in on the company. Raymond James restated an “outperform” rating and issued a $150.00 target price on shares of Sarepta Therapeutics in a research report on Thursday, October 10th. HC Wainwright dropped their price objective on Sarepta Therapeutics from $80.00 to $75.00 and set a “sell” rating on the stock in a research note on Tuesday, December 3rd. William Blair raised Sarepta Therapeutics to a “strong-buy” rating in a research note on Friday, August 30th. Cantor Fitzgerald raised Sarepta Therapeutics from a “neutral” rating to an “overweight” rating and lifted their target price for the stock from $152.00 to $167.00 in a report on Thursday, November 7th. Finally, Needham & Company LLC cut their price target on shares of Sarepta Therapeutics from $205.00 to $202.00 and set a “buy” rating for the company in a report on Wednesday, November 27th.

Sarepta Therapeutics Trading Down 0.6 %

Shares of NASDAQ:SRPT opened at $123.71 on Friday. The company has a 50 day moving average of $123.12 and a 200-day moving average of $131.30. The company has a current ratio of 3.84, a quick ratio of 3.03 and a debt-to-equity ratio of 0.93. The firm has a market cap of $11.82 billion, a P/E ratio of 98.97 and a beta of 0.77. Sarepta Therapeutics has a twelve month low of $89.92 and a twelve month high of $173.25.

Insider Buying and Selling

In other news, Director Kathryn Jean Boor sold 1,636 shares of the stock in a transaction that occurred on Thursday, December 5th. The shares were sold at an average price of $125.55, for a total value of $205,399.80. Following the completion of the sale, the director now directly owns 5,880 shares of the company’s stock, valued at $738,234. This represents a 21.77 % decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this link. Company insiders own 7.70% of the company’s stock.

Institutional Inflows and Outflows

Several large investors have recently added to or reduced their stakes in SRPT. Innealta Capital LLC purchased a new position in shares of Sarepta Therapeutics during the 2nd quarter valued at $31,000. Sunbelt Securities Inc. boosted its position in Sarepta Therapeutics by 446.2% during the third quarter. Sunbelt Securities Inc. now owns 284 shares of the biotechnology company’s stock valued at $35,000 after purchasing an additional 232 shares during the last quarter. Huntington National Bank grew its stake in Sarepta Therapeutics by 150.9% in the third quarter. Huntington National Bank now owns 291 shares of the biotechnology company’s stock valued at $36,000 after purchasing an additional 175 shares in the last quarter. Nkcfo LLC acquired a new position in Sarepta Therapeutics in the 2nd quarter worth about $43,000. Finally, Riggs Asset Managment Co. Inc. raised its stake in shares of Sarepta Therapeutics by 33.3% during the 2nd quarter. Riggs Asset Managment Co. Inc. now owns 300 shares of the biotechnology company’s stock worth $47,000 after purchasing an additional 75 shares in the last quarter. Institutional investors and hedge funds own 86.68% of the company’s stock.

Sarepta Therapeutics Company Profile

Sarepta Therapeutics, Inc, a commercial-stage biopharmaceutical company, focuses on the discovery and development of RNA-targeted therapeutics, gene therapies, and other genetic therapeutic modalities for the treatment of rare diseases. It offers EXONDYS 51 injection to treat duchenne muscular dystrophy (duchenne) in patients with confirmed mutation of the dystrophin gene that is amenable to exon 51 skipping; VYONDYS 53 for the treatment of duchenne in patients with confirmed mutation of the dystrophin gene that is amenable to exon 53 skipping; AMONDYS 45 for the treatment of duchenne in patients with confirmed mutation of the dystrophin gene; and ELEVIDYS, an adeno-associated virus based gene therapy for the treatment of ambulatory pediatric patients aged 4 through 5 years with duchenne with a confirmed mutation in the duchenne gene.